Trials / Unknown
UnknownNCT05805891
Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Chinese SLE Treatment And Research Group · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, single-arm, prospective study on the efficacy and safety of Bortezomib in addition to standard therapy in patients with refractory rheumatoid arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bortezomib | bortezomib 2mg/week subcutaneous injection |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2025-06-01
- Completion
- 2025-12-01
- First posted
- 2023-04-10
- Last updated
- 2023-08-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05805891. Inclusion in this directory is not an endorsement.